Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.58 |
| ▸ | CMA1 | P23946 | 14/20 | 0.57 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
| ▸ | REN | P00797 | 2/20 | 0.52 |
| ▸ | CTRC | Q99895 | 2/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22962350 | 0.94 | F2 (0.57) | F2PRSS1CMA1ACECTRC | |
| SCHEMBL22962154 | 0.90 | F2 (0.54) | F2PRSS1CMA1ACECTRC | |
| SCHEMBL29560799 | 0.88 | F2 (0.62) | F2PRSS1CMA1ACECTRC | |
| SCHEMBL29562010 | 0.88 | F2 (0.62) | F2PRSS1CMA1ACECTRC | |
| SCHEMBL10445408 | 0.86 | CMA1 (0.56) | F2PRSS1CMA1ACECTRC | |
| SCHEMBL10697532 | 0.86 | F2 (0.58) | F2PRSS1CMA1ACECTRC | |
| SCHEMBL29445785 | 0.86 | F2 (0.53) | F2PRSS1CMA1CTRCOPRM1 | |
| SCHEMBL20173734 | 0.86 | OPRM1 (0.54) | F2PRSS1RENOPRM1OPRD1 | |
| SCHEMBL22871631 | 0.86 | ITGB3 (0.53) | F2PRSS1CMA1RENITGB3 | |
| SCHEMBL7312472 | 0.85 | ITGB3 (0.59) | F2PRSS1CMA1ACEITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040150-A1 | KAPPA OPIOID RECEPTOR PEPTIDE AMIDE AGONISTS | YICHANG HUMANWELL PHARMACEUTICALS CO., LTD. (CN) | 2021-02-11 | — | — | US | disclosed |
| WO-2021026492-A1 | KAPPA OPIOID RECEPTOR PEPTIDE AMIDE AGONISTS | Humanwell Pharmaceutical US (US) | 2021-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040150-A1 | KAPPA OPIOID RECEPTOR PEPTIDE AMIDE AGONISTS | OPRK1, OPRL1, OPRD1 | F2 3195/4885PRSS1 2910/4885CMA1 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.